Alimera Sciences, Inc. (ALIM) Given a $5.00 Price Target by HC Wainwright Analysts
A number of other equities analysts have also recently issued reports on ALIM. ValuEngine upgraded Alimera Sciences from a sell rating to a hold rating in a report on Thursday, July 13th. Zacks Investment Research cut Alimera Sciences from a buy rating to a hold rating in a report on Thursday, July 13th. Cowen and Company restated a buy rating and set a $3.00 target price on shares of Alimera Sciences in a report on Tuesday, July 11th. Finally, Rodman & Renshaw assumed coverage on Alimera Sciences in a report on Thursday, April 27th. They set a buy rating and a $4.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) opened at 1.47 on Wednesday. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $2.40. The firm’s market cap is $95.40 million. The firm’s 50-day moving average price is $1.41 and its 200 day moving average price is $1.38.
Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.02. The business had revenue of $6.62 million during the quarter, compared to analysts’ expectations of $8.80 million. During the same quarter in the prior year, the business posted ($0.22) EPS. The company’s revenue was up 14.1% on a year-over-year basis. On average, equities analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/alimera-sciences-inc-alim-given-a-5-00-price-target-by-hc-wainwright-analysts/1462363.html.
An institutional investor recently raised its position in Alimera Sciences stock. KCG Holdings Inc. raised its stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 127.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 78,604 shares of the biopharmaceutical company’s stock after buying an additional 43,977 shares during the period. KCG Holdings Inc.’s holdings in Alimera Sciences were worth $110,000 at the end of the most recent quarter. Institutional investors and hedge funds own 43.58% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.